Startups
Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021.
Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials
in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021.
Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials
in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
Overview
Founded date
2004
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 1, 2017 | Berlin-based Cara has just secured $2 million in seed funding to help the world poop less | Cara, a Berlin-based “poop tech” startup, helps you to find out what’s good for your tummy. The young company just closed a $2 million seed financing round to launch the first precision medicine solution for digestive health. The lead inves... |
| Sep 1, 2017 | Cara Closes $2M Seed Financing | Cara, a Berlin, Germany-based precision medicine solution for digestive health, closed a $2m seed financing. The round was led by Atlantic Labs with participation from a group of angels. The company intends to use the funds to launch its so... |